10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2018 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2018 10-K (Filed: Feb 25, 2019) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2018 | Dec 31, 2017 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 6,911 | 5,421 |
| Marketable securities, current | 1,973 | 1,391 |
| Receivables | 5,965 | 6,300 |
| Inventories | 1,195 | 1,166 |
| Prepaid expenses and other | 1,116 | 576 |
| Total Current Assets | 17,160 | 14,854 |
| Property, plant and equipment | 5,027 | 5,001 |
| Goodwill | 6,538 | 6,863 |
| Other intangible assets | 1,091 | 1,210 |
| Deferred Tax Assets, Net of Valuation Allowance, Noncurrent | 1,371 | 1,610 |
| Marketable securities, noncurrent | 1,775 | 2,480 |
| Other Assets, Noncurrent | 2,024 | 1,533 |
| Total Assets | 34,986 | 33,551 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term debt obligations | 1,703 | 987 |
| Accounts payable | 1,892 | 2,248 |
| Accrued liabilities | 6,489 | 6,014 |
| Deferred income, current | 172 | 83 |
| Income taxes payable, current | 398 | 231 |
| Total Current Liabilities | 10,654 | 9,563 |
| Deferred income, noncurrent | 468 | 454 |
| Income taxes payable, noncurrent | 3,043 | 3,548 |
| Pension and other liabilities | 1,048 | 1,164 |
| Long-term debt, excluding current maturities | 5,646 | 6,975 |
| Total Liabilities | 20,859 | 21,704 |
| Commitments and contingencies | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders' Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,070 in 2017 and 4,129 in 2016, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2017 and 2016 | 221 | 221 |
| Capital in excess of par value of stock | 2,081 | 1,898 |
| Accumulated other comprehensive loss | (2,762) | (2,289) |
| Retained earnings | 34,065 | 31,160 |
| Less cost of treasury stock - 575 million common shares in 2017 and 536 million in 2016 | (19,574) | (19,249) |
| Total Bristol-Myers Squibb Company Shareholders' Equity | 14,031 | 11,741 |
| Noncontrolling interest | 96 | 106 |
| Total Equity | 14,127 | 11,847 |
| Total Liabilities and Equity | 34,986 | 33,551 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2018 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |